Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04561713
Other study ID # 2018/33
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date July 21, 2020
Est. completion date March 21, 2023

Study information

Verified date March 2022
Source University Hospital, Bordeaux
Contact Jean-Arthur MICOULAUD-FRANCHI
Phone 05 57 82 11 59
Email jean-arthur.micoulaud-franchi@chu-bordeaux.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of this study is to develop an application in order to identify the most relevant cognitive and behavioral parameters for the diagnosis of Attention Deficit Hyperactivity Disorder (ADHD) in conditions closer to reality


Description:

Attention Deficit Hyperactivity Disorder (ADHD) is the most common neurodevelopmental disorder in school-aged children. This disorder is characterized by a symptomatic triad associating, inattention, hyperactivity and impulsivity. Cognitive, emotional and behavioral dysfunctions have a strong impact on the school, family and social domains of the child. The clinical diagnosis of ADHD is all the more difficult because there are currently no biological, clinical or psychological markers that accurately measure the symptoms of ADHD. The diagnosis is made during interviews with specialist doctors allowing the collection of information from parents and the child. Virtual reality technology is most recognized as a tool for assessment, rehabilitation of cognitive processes and functional skills. In addition to traditional diagnostic assessment methods, a virtual reality application in an immersive room (CAVE) in three dimensions could objectively assess the child in a dynamic environment that is as close as possible to everyday situations


Recruitment information / eligibility

Status Recruiting
Enrollment 42
Est. completion date March 21, 2023
Est. primary completion date March 21, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 8 Years to 12 Years
Eligibility Inclusion Criteria: Group of children with ADHD : - Children aged 8 to 12 diagnosed with ADHD (according to DSM-V criteria) - Positive ADHD diagnosis with standardized maintenance of Kiddie-Sads - Naïve drug treatment for ADHD - Schooled in a classic environment - Intellectual Quotient> 80 (4 subtests of WASI, or WISC IV-R / WISC-V less than 2 years old) - Having French as mother tongue - Children benefiting from a social security scheme - Signing of free, informed and written consent by the child and the holders of parental authority Group of children controls Children aged 8 to 12 years undiagnosed ADHD (according to DSM-V criteria) : - Not presenting with ADHD at standardized maintenance Kiddie-Sads - Schooled in a classic environment - Intellectual Quotient> 80 (4 subtests of WASI) - Having French as mother tongue - Children benefiting from a social security scheme - Signing of free, informed and written consent by the child and the holders of parental authority Exclusion Criteria: - Positive diagnosis with standardized maintenance of Kiddie-Sads for the following disorders: mood disorders, psychotic disorders, autism spectrum disorders, severe anxiety disorders and severe tic disorders - Presenting a hearing or vision diagnosis diagnosed that does not allow the task to be performed in virtual reality - Neurological disorders - Photosensitive Epilepsy (contraindication to immersion in virtual reality) - Treatment with psychostimulants or other psychotropic drugs - Unable to complete the virtual reality task during the familiarization session

Study Design


Related Conditions & MeSH terms

  • Attention Deficit Disorder with Hyperactivity
  • Attention Deficit Hyperactivity Disorder
  • Hyperkinesis

Intervention

Procedure:
Virtual reality task
Virtual reality application in an immersive room (CAVE) in three dimensions to assess child's sustained attention in a dynamic environment that is as close as possible to everyday situations.

Locations

Country Name City State
France CHU de Bordeaux Bordeaux

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Bordeaux

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Average number of commission errors Average number of commission errors to the virtual reality task From one day to 8 weeks after day 0
Secondary Average reaction time (ms) The average reaction time (ms) to the virtual reality task From one day to 8 weeks after day 0
Secondary Average number of omission errors Average number of omission errors to the virtual reality task From one day to 8 weeks after day 0
Secondary Average number of head movement The average amount of head movement to the virtual reality task From one day to 8 weeks after day 0
Secondary Average number of foot movement The average amount of foot movement to the virtual reality task From one day to 8 weeks after day 0
Secondary Percentage The percentage of periods with emotions during the virtual reality task From one day to 8 weeks after day 0
Secondary Percentage of period with presence of Emotion Percentage of period with presence of Emotion (Engagement > 50) during the task of virtual reality (range from 0 to 100). From one day to 8 weeks after day 0
Secondary Mean Emotion intensity (Engagement) Mean Emotion intensity (Engagement) during the task of virtual reality (range from 0 to 100). From one day to 8 weeks after day 0
Secondary Mean Emotion valence Mean Emotion valence (negative or positive emotion) during the task of virtual reality (range from -100 to 100). From one day to 8 weeks after day 0
Secondary Average reaction time (ms) The average reaction time (ms) to the Continuous Performance Test (CPT) wich is a neuropsychological assessment test of sustained attention Day 0
Secondary Average number of commission errors The average number of commission errors to the CPT neuropsychological task Day 0
Secondary Average number of omission errors The average number of omission errors to the CPT neuropsychological task Day 0
Secondary Total score with the Attention-Deficit Hyperactivity Disorder-Rating Scale. Scale to assess the severity of the 18 symptoms of DSM related to ADHD, the higher score mean a worse outcome. Max value : 54 Day 0
Secondary Inattention score with the Attention-Deficit Hyperactivity Disorder-Rating Scale Inattention score with the Attention-Deficit Hyperactivity Disorder-Rating Scale. With inattention (items impairs) max value = 27, the higher score mean a worse outcome Day 0
Secondary Hyperactivity score with the Attention-Deficit Hyperactivity Disorder-Rating Scale Hyperactivity score with the Attention-Deficit Hyperactivity Disorder-Rating Scale. Hyperactivity (items pairs) max value=27, the higher score mean a worse outcome Day 0
Secondary Executive Performance Inventory Score Executive Performance Inventory Score with Behavior Rating Inventory of Executive Function (BRIEF) questionnaire. Min value=30 and max value=100 the higher score mean a worse outcome. Day 0
Secondary Quality of life (VSPA-e) score Quality of life score with VSPA-e questionnaire. Min value= 0 and max value=100 the higher score mean a worse outcome Day 0
Secondary Quality of life (KIDSCREEN) score Quality of life with KIDSCREEN questionnaire. Min value= 0 and max value=100 the higher score mean a better outcome. Day 0
Secondary Acceptability score of virtual reality tool Acceptability score of virtual reality tool. Min value= 6 and max value=30 the higher score mean a better outcome. From one day to 8 weeks after day 0
Secondary Acceptability score of classic neuropsychological test Acceptability score of classic neuropsychological test. Min value= 6 and max value=30 the higher score mean a better outcome. From one day to 8 weeks after day 0
Secondary Simulator Sickness score Score on the "Simulator Sickness" questionnaire. Min value= 0 and max value=63 the higher score mean a worse outcome. From one day to 8 weeks after day 0
Secondary Feeling of presence score Score at the "feeling of presence" scale. Min value= -42 and max value=+42 The higher score mean a better immersion. From one day to 8 weeks after day 0
See also
  Status Clinical Trial Phase
Recruiting NCT06129396 - Effects of Aerobic Exercise Intervention in Adolescents With Attention-deficit/Hyperactivity Disorder (ADHD) N/A
Completed NCT04779333 - Lifestyle Enhancement for ADHD Program 2 N/A
Recruiting NCT05935722 - Evaluation of a Home-based Parenting Support Program: Parenting Young Children N/A
Completed NCT03148782 - Brain Plasticity Underlying Acquisition of New Organizational Skills in Children-R61 Phase N/A
Completed NCT04832737 - Strength-based Treatment Approach for Adults With ADHD N/A
Recruiting NCT04631042 - Developing Brain, Impulsivity and Compulsivity
Recruiting NCT05048043 - Development of a Game-supported Intervention N/A
Completed NCT03337646 - Evaluation of the Effect and Safety of Lisdexamfetamine in Children Aged 6-12 With ADHD and Autism Phase 4
Not yet recruiting NCT06406309 - Settling Down for Sleep in ADHD: The Impact of Sensory and Arousal Systems on Sleep in ADHD N/A
Not yet recruiting NCT06080373 - Formulation-based CBT for Adult Inmates With ADHD: A Randomized Controlled Trial N/A
Not yet recruiting NCT06454604 - Virtual Reality Treatment for Emerging Adults With ADHD Phase 2
Completed NCT02477280 - Effects of Expectation, Medication and Placebo on Objective and Self-rated Performance Phase 4
Completed NCT02911194 - a2 Milk for Autism and Attention-deficit Hyperactivity Disorder (ADHD) N/A
Completed NCT02473185 - Effects of Expectation, Medication and Placebo on Objective and Self-rated Performance During the QbTest Phase 4
Completed NCT02829970 - Helping College Students With ADHD Lead Healthier Lifestyles N/A
Completed NCT02780102 - Cognitive-Motor Rehabilitation, Stimulant Drugs, and Active Control in the Treatment of ADHD N/A
Completed NCT02390791 - New Technologies to Help Manage ADHD N/A
Completed NCT02555150 - A Comparison of PRC-063 and Lisdexamfetamine in the Driving Performance of Adults With ADHD Phase 3
Recruiting NCT04175028 - Neuromodulation of Executive Function in the ADHD Brain N/A
Recruiting NCT04296604 - Transcranial Direct Current Stimulation (tDCS) Neuromodulation of Executive Function Across Neuropsychiatric Populations N/A